We are international
Donate
• about myeloma TEXT SIZE   
the understanding series    back

IMF REPORTS POSITIVE SHIFT IN TREATMENT PARADIGM FOR PATIENTS
Second Closure of Multi-Center Trial in 4 Weeks Reinforces Benefits of Using REVLIMID® with Low Dose Steroids in Myeloma
05.15.07

Be the first to comment

 related articles